GlassScriptPhysician profile
Mark A Kozinn
NPI 1184696973
$2,560.42
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $509 · 2021: $924 · 2022: $891 · 2023: $36.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $36.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $36.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $344.32 | 2021-2023 | |
| Upsher-Smith Laboratories LLC | $243.88 | 2020-2022 | |
| Genzyme Corporation | $167.54 | 2019-2022 | |
| Emd Serono, INC. | $144.29 | 2019-2022 | |
| Ucb, INC. | $143.40 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $136.93 | 2019-2021 | |
| Sk Life Science, INC. | $136.20 | 2020 | |
| Amgen INC. | $84.37 | 2020-2022 | |
| Ge Healthcare | $84.03 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $79.22 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $69.53 | 2020-2021 | |
| Allergan, INC. | $67.80 | 2020-2022 | |
| Kyowa Kirin, INC. | $67.51 | 2020-2022 | |
| Biogen, INC. | $63.30 | 2019-2022 | |
| Lundbeck LLC | $62.91 | 2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $57.51 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.85 | 2022 | |
| Janssen Pharmaceuticals, INC | $51.83 | 2022 | |
| Grifols USA, LLC | $44.97 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $33.93 | 2021-2022 | |
| Neurelis, INC. | $33.65 | 2021-2022 | |
| Celgene Corporation | $32.43 | 2021 | |
| Amneal Pharmaceuticals LLC | $30.57 | 2020 | |
| Horizon Therapeutics Plc | $29.85 | 2022 | |
| Vertical Pharmaceuticals, LLC | $26.88 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.90 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $23.09 | 2021 | |
| Aprecia Pharmaceuticals, LLC | $23.06 | 2020 | |
| Argenx US, INC. | $22.33 | 2022 | |
| Livanova USA, INC. | $22.15 | 2021 | |
| Genentech USA, INC. | $21.43 | 2022 | |
| Jazz Pharmaceuticals INC. | $21.02 | 2022 | |
| Greenwich Biosciences, INC. | $19.60 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18.37 | 2021 | |
| Impel Pharmaceuticals INC. | $18.03 | 2022 | |
| Pfizer INC. | $15.49 | 2021 | |
| Lilly USA, LLC | $14.24 | 2022 | |
| United Therapeutics Corporation | $11.96 | 2019 | |
| Advanced Respiratory, INC | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kozinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.